OCT 10, 2019 9:00 AM PDT

Next Generation Targets for Immuno-Oncology

Sponsored by: Bio-Techne
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Sr. Director, Protein Business Unit, R&D Systems
    Biography
      Anthony received his Ph.D. in Cell Biology and Anatomy at the University of Arizona where his research concentrated on understanding the molecular mechanisms of cardiac valve development. He moved onto a Postdoctoral Research Fellowship at the University of Minnesota where he utilized zebrafish and mouse model systems to uncover new genes involved in kidney and heart development and also published the genetic cause of the dwarfing syndrome in humans called dominant Robinow Syndrome. Anthony spent time in the Stem Cell biotech industry using mRNA overexpression to reprogram somatic cells to pluripotency as well as transdifferentiating one cell type into another. Finally, Anthony has been at R&D Systems for the last 8 years working as a Manager and then Director in the Protein Development Department. Anthony has over 12 years of Biotech industry experience and is focused on offering the highest quality recombinant proteins to customers. New protein product offerings in the Immuno-oncology area is a major focus for R&D Systems as so many academic and biotech/pharma labs are entering this area with the success of both antibody immunotherapy as well as CAR T or CAR NK research and therapies.

    Abstract

    Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family members, novel immunoregulatory pathways are being uncovered as potential targets for oncology research and cancer immunotherapy. In this presentation, we discuss some of the next generation of novel immune checkpoint molecules, including Butyrophilins (BTNs), leukocyte immunoglobulin-like receptors (LILRs), and V-Set and Immunoglobulin domain containing (VSIGs). Specifically, we will present data demonstrating that bioactive recombinant Butyrophilin proteins (BTN1A1, BTN2A2, and BTN3A1) are T cell inhibitory modulators that inhibit cytokine secretion and cell proliferation on anti-CD3 activated T cells. We will also show data identifying ANGPTL proteins as novel LILR receptors and discuss a novel group of proteins termed V-Set And Immunoglobulin Domain-Containing (VSIG).


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    OCT 10, 2019 9:00 AM PDT

    Next Generation Targets for Immuno-Oncology

    Sponsored by: Bio-Techne
    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Molecular Biology

    Assay Development

    Cancer Therapeutics

    Genomics

    Gene Sequencing

    Cell Biology

    Molecular Diagnostics

    Immunology

    Oncology

    Cancer Research

    Animal Research

    Medicine

    Gene Therapy

    Cell Signaling / Transduction

    Pcr/rt-Pcr/real-Time Pcr

    Geography

    North America80%

    Asia20%

    Registration Source

    Website Visitors100%

    Job Title

    Facility/Department Manager33%

    Educator/Faculty33%

    Scientist33%

    Organization

    Academic Institution40%

    Hospital20%

    Clinical Laboratory20%

    Contract Research Organization (Cro)20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more